Bayer: trial shows potential of Nubeqa
(CercleFinance.com) - Bayer has announced that a Phase III trial showed that Nubeqa (darolutamide), in combination with docetaxel and androgen deprivation therapy (ADT), significantly increases the overall survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared to treatment with docetaxel and ADT alone.
Bayer says that detailed results of the study are expected to be presented at an upcoming scientific meeting.
The company plans to discuss the data from this trial with health authorities around the world as part of a marketing authorisation application for this indication.
Currently, darolutamide is approved in several markets around the world under the brand name Nubeqa to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
Copyright (c) 2021 CercleFinance.com. All rights reserved.